Actinium Pharmaceuticals, Inc. is a leading clinical-stage biopharmaceutical firm focused on developing cutting-edge therapies for bone marrow transplantation and adoptive cell therapies, with a primary emphasis on hematologic malignancies. Based in New York, the company is advancing its proprietary antibody-radionuclide conjugate platform, aimed at improving patient outcomes in both transplantation and cancer care. With a promising pipeline of therapeutic candidates and strategic collaborations, Actinium is well-positioned to tackle significant unmet medical needs in the oncology sector, making it a compelling prospect for institutional investors seeking innovation in biopharmaceuticals.

NYSE MKT

USA

HEALTHCARE

BIOTECHNOLOGY

100 PARK AVENUE, NEW YORK, NY, UNITED STATES, 10017

December

$44.6 Million

-$44 Million

0.0

-1.31

$0.00

0.0%

-0.366